Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, +11

Proceedings of the National Academy of Sciences

EngineeringChemoprevention StrategySmarcb1-deleted Mrt CellsPathologyCancer Biology +22

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, +18

Nature Chemical Biology

Lymphoid NeoplasiaMedicineSelective InhibitorAnti-cancer AgentTumor Suppressor +6

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, +17

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologySolid Tumours +6

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i> -Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, +23

Molecular Cancer Therapeutics

Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Mohamed Bentires‐Alj, J. Guillermo Paez, Frank David, +18

Cancer Research

Loss of BAP1 function leads to EZH2-dependent transformation

Lindsay M. LaFave, Wendy Béguelin, Richard P. Koche, +28

Nature Medicine

ChromatinSignal TransductionSignal RecognitionMolecular BiologyMedicine +1

Diverse Biochemical Properties of Shp2 Mutants

Heike Keilhack, Frank David, Malcolm J. McGregor, +2

Journal of Biological Chemistry

Molecular BiologyTumor BiologySignaling PathwayCell RegulationShp2 Mutants +14

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations

M. Golam Mohi, Ifor R. Williams, Charles R. Dearolf, +10

Cancer Cell

Knockout MouseGenome InstabilitySignal TransductionMixed-phenotype Acute LeukemiaSystems Biology +5

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo, +25

Cancer Cell

CytokineCancer ImmunosurveillanceMedicineImmunologyTumor Immunity +7

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Kevin W. Kuntz, John E. Campbell, Heike Keilhack, +11

Journal of Medicinal Chemistry

Histone ModificationsEpigenetic ChangePharmacotherapyEpigeneticsTumor Biology +20